EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders

Sanya Thomas, Jensen Pak, Simon Doss-Gollin, Kevin Ryff, Elisabeth Beijnen, Gabriel K Pedersen, Dennis Christensen, Ofer Levy, Simon D van Haren

Journal of Molecular Biology · 2024-02 · 436 (4) · 168446

DOI: 10.1016/j.jmb.2024.168446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Biology, 2024-02. Verfasst von Sanya Thomas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, …. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, Cross-Priming, Th1 Cells, Viral Vaccines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvants are vaccine components that can boost the type, magnitude, breadth, and durability of an immune response. We have previously demonstrated that certain adjuvant combinations can act synergistically to enhance and shape immunogenicity including promotion of Th1 and cytotoxic T-cell development. These combinations also promoted protective immunity in vulnerable populations such as newborns. In this study, we employed combined antigen-specific human in vitro models to identify adjuvant combinations that could synergistically promote the expansion of vaccine-specific CD4+ cells, induce cross-presentation on MHC class I, resulting in antigen-specific activation of CD8+ cells, and direct the balance of immune response to favor the production of Th1-promoting cytokines. A screen of 78 adjuvant combinations identified several T cell-potentiating adjuvant combinations. Remarkably, a combination of TLR9 and STING agonists (CpG + 2,3-cGAMP) promoted influenza-specific CD4+ and CD8+ T cell activation and selectively favored production of Th1-polarizing cytokines TNF and IL-12p70 over co-regulated cytokines IL-6 and IL-12p40, respectively. Phenotypic reprogramming towards cDC1-type dendritic cells by CpG + 2,3-cGAMP was also observed. Finally, we characterized the molecular mechanism of this adjuvant combination including the ability of 2,3-cGAMP to enhance DC expression of TLR9 and the dependency of antigen-presenting cell activation on the Sec22b protein important to endoplasmic reticulum-Golgi vesicle trafficking. The identification of the adjuvant combination CpG + 2,3-cGAMP may therefore prove key to the future development of vaccines against respiratory viral infections tailored for the functionally distinct immune systems of vulnerable populations such as older adults and newborns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, ImmunologicCross-PrimingTh1 CellsViral VaccinesVaccine DevelopmentHumansInfant, NewbornCytokinesDendritic CellsToll-Like Receptor 9AdolescentYoung Adult

Stichwörter der Autor:innen

AdjuvantAdultCD4CD8Dendritic cellNewbornOlder adultVaccine

Substanzen

Adjuvants, ImmunologicCytokinesToll-Like Receptor 9Viral Vaccines

Autor:innen und Institutionen

  • Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
  • Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark; Department of Immunology and Microbiology, University of Copenhagen, Denmark.
  • Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.
  • Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Boston Children's Ho…
  • Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA. Electronic address: simon.vanharen@childrens.harvard.…

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health
  • Bill and Melinda Gates Foundation

Zitieren

APA

Thomas, S., Pak, J., Doss-Gollin, S., Ryff, K., Beijnen, E., Pedersen, G. K., Christensen, D., Levy, O., & van Haren, S. D. (2024). Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders. Journal of Molecular Biology, 436(4), 168446. https://doi.org/10.1016/j.jmb.2024.168446

Vancouver

Thomas S, Pak J, Doss-Gollin S, Ryff K, Beijnen E, Pedersen GK, et al. Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders. Journal of Molecular Biology. 2024;436(4):168446. doi:10.1016/j.jmb.2024.168446

BibTeX
@article{Thomas2024,
  author = {Thomas, Sanya and Pak, Jensen and Doss-Gollin, Simon and Ryff, Kevin and Beijnen, Elisabeth and Pedersen, Gabriel K and Christensen, Dennis and Levy, Ofer and van Haren, Simon D},
  title = {Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders},
  journal = {Journal of Molecular Biology},
  year = {2024},
  volume = {436},
  number = {4},
  pages = {168446},
  doi = {10.1016/j.jmb.2024.168446}
}
Kostenlos starten →